Institution
Shahid Beheshti University of Medical Sciences and Health Services
Education•Tehran, Iran•
About: Shahid Beheshti University of Medical Sciences and Health Services is a education organization based out in Tehran, Iran. It is known for research contribution in the topics: Population & Medicine. The organization has 19456 authors who have published 33659 publications receiving 365676 citations.
Topics: Population, Medicine, Cancer, Breast cancer, Randomized controlled trial
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A Confounder is a variable whose presence affects the variables being studied so that the results do not reflect the actual relationship.
Abstract: A Confounder is a variable whose presence affects the variables being studied so that the results do not reflect the actual relationship. There are various ways to exclude or control confounding variables including Randomization, Restriction and Matching. But all these methods are applicable at the time of study design. When experimental designs are premature, impractical, or impossible, researchers must rely on statistical methods to adjust for potentially confounding effects. These Statistical models (especially regression models) are flexible to eliminate the effects of confounders.
373 citations
••
University of Milan1, Cairo University2, Jehangir Hospital3, Shahid Beheshti University of Medical Sciences and Health Services4, Shiraz University of Medical Sciences5, St. John's Medical College6, University of Southern California7, All India Institute of Medical Sciences8, Mexican Social Security Institute9, University of the Witwatersrand10, Medical University of Vienna11, City of Hope National Medical Center12, Alfaisal University13, Rush University Medical Center14, University of Mississippi15, Çukurova University16, Ege University17, University of Colorado Denver18, Ain Shams University19, Sapienza University of Rome20, Johannes Kepler University of Linz21, Children's Mercy Hospital22, Istanbul University23, Leiden University24
TL;DR: Patients treated with plasma-derived factor VIII containing von Willebrand factor had a lower incidence of inhibitors than those treated with recombinant factor VIII, and this association did not change in multivariable analysis.
Abstract: BackgroundThe development of neutralizing anti–factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. MethodsWe conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age <6 years, severe hemophilia A, and no previous treatment with any factor VIII concentrate or only minimal treatment with blood components) were included from 42 sites. ResultsOf 303 patients screened, 264 underwent randomization and 251 were analyzed. Inhibitors developed in 76 patients, 50 of whom had high-titer inhibitors (≥5 Bethesda units). Inhibitors developed in 29 of the 125 patients treated with plasma-derived factor VIII (20 patients had high-titer inhibitors) and in 47 of the 126 patients treated with recombinant factor VIII (30 patients had high-titer inhib...
371 citations
••
TL;DR: Recognition of new avenues for selective COX-2 inhibitors in cancer chemotherapy and neurological diseases such as Parkinson and Alzheimer’s diseases still continues to attract investigations on the development of COX2 inhibitors.
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are the competitive inhibitors of cyclooxygenase (COX), the enzyme which mediates the bioconversion of arachidonic acid to inflammatory prostaglandins (PGs). Their use is associated with the side effects such as gastrointestinal and renal toxicity. The therapeutic anti-inflammatory action of NSAIDs is produced by the inhibition of COX-2, while the undesired side effects arise from inhibition of COX-1 activity. Thus, it was though that more selective COX-2 inhibitors would have reduced side effects. Based upon a number of selective COX-2 inhibitors (rofecoxib, celecoxib, valdecoxib etc.) were developed as safer NSAIDs with improved gastric safety profile. However, the recent market removal of some COXIBs such as rofecoxib due to its adverse cardiovascular side effects clearly encourages the researchers to explore and evaluate alternative templates with COX-2 inhibitory activity. Recognition of new avenues for selective COX-2 inhibitors in cancer chemotherapy and neurological diseases such as Parkinson and Alzheimer’s diseases still continues to attract investigations on the development of COX-2 inhibitors. This review highlights the various structural classes of selective COX-2 inhibitors with special emphasis on their structure-activity relationships.
350 citations
••
TL;DR: A significant proportion of HCWs had poor knowledge of its transmission and symptom onset and showed positive perceptions of COVID-19, and educational interventions are urgently needed to reach HCWs worldwide.
Abstract: Background: During the first week of March, the coronavirus disease 2019 (COVID-19) outbreak reached more than 100 countries with over 100,000 cases. Health care authorities have already initiated awareness and preparedness activities worldwide. A poor understanding of the disease among health care workers (HCWs) may result in delayed treatment and result in the rapid spread of the infection.
Objective: This study aimed to investigate the knowledge and perceptions of HCWs about COVID-19.
Methods: A cross-sectional, web-based study was conducted among HCWs about COVID-19 during the first week of March 2020. A 23-item survey instrument was developed and distributed randomly to HCWs using social media; it required 5 minutes to complete. A chi-square test was used to investigate the level of association among variables, with significance set to P<.05.
Results: Of 529 participants, a total of 453 HCWs completed the survey (response rate: 85.6%); 51.6% (n=234) were male, 32.1% (n=147) were aged 25-34 years, and most were doctors (n=137, 30.2%) and medical students (n=134, 29.6%). Most participants (n=276, 61.0%) used social media to obtain information on COVID-19. A significant proportion of HCWs had poor knowledge of its transmission (n=276, 61.0%) and symptom onset (n=288, 63.6%) and showed positive perceptions of COVID-19. Factors such as age and profession were associated with inadequate knowledge and a poor perception of COVID-19.
Conclusions: As the global threat of COVID-19 continues to emerge, it is critical to improve the knowledge and perceptions of HCWs. Educational interventions are urgently needed to reach HCWs worldwide, and further studies are warranted.
342 citations
••
TL;DR: The purpose of this review was to present the current status of the knowledge and understanding of the involvement of mitochondrial dysfunction in pathogenesis of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) and the importance of mitochondrial biogenesis as a potential novel therapeutic target for their treatment.
Abstract: Neurodegenerative diseases are a heterogeneous group of disorders that are incurable and characterized by the progressive degeneration of the function and structure of the central nervous system (CNS) for reasons that are not yet understood. Neurodegeneration is the umbrella term for the progressive death of nerve cells and loss of brain tissue. Because of their high energy requirements, neurons are especially vulnerable to injury and death from dysfunctional mitochondria. Widespread damage to mitochondria causes cells to die because they can no longer produce enough energy. Several lines of pathological and physiological evidence reveal that impaired mitochondrial function and dynamics play crucial roles in aging and pathogenesis of neurodegenerative diseases. As mitochondria are the major intracellular organelles that regulate both cell survival and death, they are highly considered as a potential target for pharmacological-based therapies. The purpose of this review was to present the current status of our knowledge and understanding of the involvement of mitochondrial dysfunction in pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) and the importance of mitochondrial biogenesis as a potential novel therapeutic target for their treatment. Likewise, we highlight a concise overview of the key roles of mitochondrial electron transport chain (ETC.) complexes as well as mitochondrial biogenesis regulators regarding those diseases.
321 citations
Authors
Showing all 19557 results
Name | H-index | Papers | Citations |
---|---|---|---|
Paul F. Jacques | 114 | 446 | 54507 |
Mohammad Abdollahi | 90 | 1045 | 35531 |
Fereidoun Azizi | 80 | 1279 | 41755 |
Roya Kelishadi | 73 | 853 | 33681 |
Nima Rezaei | 72 | 1215 | 26295 |
Neal D. Freedman | 68 | 327 | 16908 |
Jamie E Craig | 68 | 380 | 15956 |
Amir Hossein Mahvi | 63 | 686 | 15816 |
Adriano G. Cruz | 61 | 346 | 12832 |
Ali Montazeri | 61 | 625 | 17494 |
Parvin Mirmiran | 56 | 637 | 15420 |
Harry A. Lando | 53 | 242 | 9432 |
Fatemeh Atyabi | 53 | 310 | 9985 |
Daniel Granato | 53 | 235 | 9406 |
Pejman Rohani | 52 | 192 | 13386 |